Priemer DS, Montironi R, Wang L, Williamson SR, Lopez-Beltran A, Cheng L. Neuroendocrine tumors of the prostate: Emerging insights from molecular data and updates to the 2016 World Health Organization Classification. Endocr Pathol 2016; 27: 123-135.

Article  CAS  PubMed  Google Scholar 

Montironi R, Cimadamore A, Lopez-Beltran A, Scarpelli M, Cheng LMorphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer. Cells. 2020;9(5): 1073.

Mohanty SK, Lobo A, Williamson SR, et al. Reporting Trends, Practices, and Resource Utilization in Neuroendocrine Tumours of the Prostate Gland: A Survey among Thirty-Nine Genitourinary Pathologists. Int J Surg Pathol. 2023;31(6):993-1005.

Article  PubMed  Google Scholar 

Puca L, Vlachostergios PJ, Beltran H. Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies. Cold Spring Harb Perspect Med. 2019;9(2):a030593.

Article  PubMed  PubMed Central  Google Scholar 

Monn MF, Cheng L. Emerging trends in the evaluation and management of small cell prostate cancer: A clinical and molecular perspective. Expert Rev Anticancer Ther 2016; 16:1029-1037.

Article  CAS  PubMed  Google Scholar 

Epstein JI, Amin MB, Beltran H, et al. Proposed Morphologic Classification of Prostate Cancer with Neuroendocrine Differentiation. Am J Surg Pathol. 2014;38(6):756-767.

Article  PubMed  PubMed Central  Google Scholar 

Santoni M, Conti A, Burattini L, Berardi R, Scarpelli M, Cheng L. Neuroendocrine differentiation in prostate cancer: Novel morphological insights and future therapeutic perspectives. Biochim Biophys Acta 2014; 1846:630-637.

CAS  PubMed  Google Scholar 

Mohanty SK, Lobo A, Cheng L. The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges. Hum Pathol. 2023;136:123-143.

Article  PubMed  Google Scholar 

WHO Classification of Tumours Editorial Board. WHO Classification of Tumours: Urinary and Male Genital Tumours. 5th ed, Vol 8, Lyon (France): Internnational Agency for Rsearch on Cancer (IARC), 2022.

Monn MF, Montironi R, Lopez-Beltran A, Cheng L. Emerging Molecular Pathways and Targets in Neuroendocrine Prostate Cancer. Transl Cancer Res 5(S2): S282-S285, 2016.

Article  CAS  Google Scholar 

Fine SW. Neuroendocrine tumors of the prostate. Mod Pathol. 2018;31(S1):S122-132.

Article  PubMed  Google Scholar 

Cheng L, MacLennan GT, Bostwick DG. Urologic Surgical Pathology, 5th edition, Elsevier, Philadelphia, PA, 2026.

Google Scholar 

Gopalan A. Treatment-related Neuroendocrine Prostate Carcinoma-Diagnostic and Molecular Correlates. Adv Anat Pathol. 2024;31(2):70-79.

Article  CAS  PubMed  Google Scholar 

Wang Y, Wang Y, Ci X et al. Molecular events in neuroendocrine prostate cancer development. Nat Rev Urol. 2021;18(10):581-596.

Article  PubMed  PubMed Central  Google Scholar 

Beltran H, Hruszkewycz A, Scher HI, et al. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clin Cancer Res. 2019;25(23):6916-6924.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pignon JC, Grisanzio C, Geng Y, et al. p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia. Proc Natl Acad Sci USA. 2013;110(20):8105-8110.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yao JL, Madeb R, Bourne P, et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol. 2006;30(6):705-712.

Article  PubMed  Google Scholar 

Shehabeldin AN, Ro JY. Neuroendocrine tumors of genitourinary tract: Recent advances. Ann Diagn Pathol. 2019;42:48-58.

Article  PubMed  Google Scholar 

Scheble VJ, Braun M, Wilbertz T, et al. ERG rearrangement in small cell prostatic and lung cancer. Histopathology. 2010;56(7):937-943.

Article  PubMed  Google Scholar 

Wang L, Williamson SR, Zhang S, et al. Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma. Mol Carcinog. 2015;54(9):900-907.

Article  CAS  PubMed  Google Scholar 

Linja MJ, Savinainen KJ, Saramäki OR, et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001;61(9):3550-3555.

CAS  PubMed  Google Scholar 

Faisal FA, Lotan TL. The Genomic and Molecular Pathology of Prostate Cancer: Clinical Implications for Diagnosis, Prognosis, and Therapy. Adv Anat Pathol. 2020 ;27(1):11-19.

Article  CAS  PubMed  Google Scholar 

Abdulfatah E, Fine SW, Lotan TL, et al. De novo neuroendocrine features in prostate cancer. Hum Pathol. 2022;127:112-122.

Article  CAS  PubMed  Google Scholar 

Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of PTEN-deficient tumorigenesis. Nature. 2005;436(7051):725-730.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ku SY, Rosario S, Wang Y, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355(6320):78-83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mu P, Zhang M, Benelli WR, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 and RB1 deficient prostate cancer. Science. 2017;355:84–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akamatsu S, Inoue T, Ogawa O, et al. Clinical and molecular features of treatment-related neuroendocrine prostate cancer. Int J Urol. 2018;25(4):345-351.

Article  CAS  PubMed  Google Scholar 

Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487–495.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beltran H, Oromendia C, Danila DC, et al. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin Cancer Res. 2019;25(1):43-51.

Article  CAS  PubMed  Google Scholar 

Park K, Chen Z, MacDonald TY, et al. Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. Hum Pathol. 2014; 45(10):2136–2143.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Kouchkovsky I, Chan E, Schloss C, Poehlein C, Aggarwal R. Diagnosis and management of neuroendocrine prostate cancer. Prostate. 2024;84(5):426-440.

Article  PubMed  Google Scholar 

Chiaverotti T, Couto SS, Donjacour A, et al. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol. 2008;172(1):236-246.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rudin CM, Poirier JT, Byers LA, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19(5):289-297.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rodarte KE, Nir Heyman S, Guo L et al. Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1. Cancer Res. 2024;84(21):3522-3537.